Trevi Therapeutics has announced that its Phase IIb CORAL trial of Haduvio in treating idiopathic pulmonary fibrosis (IPF) subjects with chronic cough, will continue with its current sample size ...

The main symptom of idiopathic pulmonary fibrosis is dyspnea during exercise. As the disease progresses, a dry cough becomes worse and shortness of breath worsens, which can lead to hypoxia.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A dry, persistent cough that doesn’t respond to typical cough medications frequently accompanies early IPF. This cough often worsens during physical activity and can become quite disruptive to ...

New treatment approach shows potential in reversing lung damage caused by idiopathic pulmonary fibrosis using immune-based ...

Patients with IPF have an average life expectancy of just three to five years, during which time symptoms like cough, fatigue and shortness of breath get worse, and around two thirds of them ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and ...

"The RIVER trial demonstrated that Haduvio was highly effective, and worked quickly at the lowest dose tested across a broad range of cough counts. These results, coupled with our existing IPF ...

We look forward to our expected readout of topline results for the Phase 2b CORAL trial in IPF chronic cough patients in the second quarter of this year." To participate in the live conference ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...